INTERVIEWS

Holiday season is right around the corner and for people living with overactive bladder, it can cause a lot of stress and anxiety about visiting family or friends, traveling and even avoiding certain holiday  meals that can irritate the bladder.   In this segment, Diane Newman, a nurse practitioner specializing in urology and a spokesperson for Urovant Sciences discusses overactive bladder and offers tips to help manage this common condition.

Dr. Lori Panther, MD, MPH, Vice President of Clinical Development, Infectious Diseases at Moderna discusses a virus that is the leading infectious cause of birth defects in the US called CMV or cytomegalovirus which has no vaccine. She talks about the current research on a CMV vaccine. She is joined by Shayne Gaffney, parent of a child with CMV who is bringing awareness to the illness and his goal is to push for universal CMV screening…and educate other parents about the virus. 

Corey Lawson, Vice President of Product Strategy at Accuray, a company that develops unique market-changing radiotherapy solutions, discusses the fast changing radiation therapy landscape and the new partnership with C-RAD to enhance the Accuray Radixact ® System’s ability to treat breast cancer. 

April N. Kapu, President, American Association of Nurse Practitioners ® and certified acute care nurse practitioner (NP) discusses the purpose of National Nurse Practitioner Week, November 7-13, the dedication and commitment of NPs during the last year and a half treating COVID patients and how the role and responsibilities of NPs evolved during the pandemic. She talks about the nursing shortage and what can be/is being done to help draw new nurses and NPs into the profession. 

Marilyn C​, stage 4 lung cancer survivor discusses her treatment journey with immunotherapy, how she dealt with the stigma and misinformation associated with the disease, and the importance of lung cancer screenings.

Dr. Lisa Barroilhet, Associate Professor in the department of Obstetrics and Gynecology at the University of Wisconsin School of Medicine and Public Health discusses the launch of the program #MoveTheMessage making educational materials available to patients, and giving access to medical professionals to use the materials and direct patients to them. A survey of gynecologic oncologists found that most felt that access to patient education materials is an important part of patient outcomes and feel that there is a great need for access to online educational resources.

In this episode, Dr. James “Jim” K. Min, CEO of  Cleerly Health, a company whose mission is to up level the standard approaches to monitoring heart disease that have been used for decades, discusses its advanced non-invasive CT imaging. The advanced imaging allows physicians to monitor and characterize atherosclerosis (plaque) buildup, the primary disease that  causes heart attacks, to accurately determine a patient’s risk of a heart attack.  Dr. Min shares how this approach is more effective and efficient compared to historical manual tests, how  it is  helping patients identify their cardiovascular diseases and develop a treatment plan and how the healthcare system needs to use advanced imaging to prevent heart disease, similar to how it’s done in cancer care.   

Returning guest, Dave Ross, Vice President, Commercial Operations, North America at Seqirus discusses the FDA approval of the first and only cell-based influenza vaccine in the U.S., FLUCELVAX QUADRIVALENT for an expanded age indication for children as young as six months old. As a global leader in influenza prevention, this approval reinforces Seqirus’ commitment to developing innovative influenza vaccine technologies to protect as many eligible people as possible, particularly those in vulnerable populations and especially considering the ongoing COVID-19 pandemic. 

Returning guest, Dr. Gregg Sylvester, MD, Chief Medical Officer at Seqirus, ​one of the world’s largest influenza vaccine providers discusses some new real-world evidence that was presented at the global International Society for Influenza and other Respiratory Virus Diseases (ISIRV) – World Health Organization (WHO) Virtual Conference that showed that cell-based quadrivalent seasonal influenza (QIVc) vaccines were more effective in children and adults and adjuvanted trivalent seasonal influenza vaccines (aTIV) were more effective in older populations. 

Ronald Martell, President and CEO at MorphImmune discusses MorphImmune’s proprietary platform that enables reprogramming or removal of aberrant cells with targeted effector molecules linked to precision small molecules and is further designed to enable the creation of countless combinations of targeted molecules to treat a wide variety of diseases effectively and safely. The company’s discovery platform has enabled the identification of 10+ additional targets for consideration.